Noxopharm Investigating Potential COVID-19 Treatment
1 April 2020 Noxopharm (NOX:ASX) announces that the Hudson Institute of Medical Research (Hudson Institute) in Melbourne has identified that idronoxil inhibits a key inflammatory pathway involved in a process known as a cytokine storm. Cytokine storm is…
Where are we at with developing a vaccine for coronavirus?
3 April 2020 This article is republished from The Conversation under a Creative Commons license. Read the original article. Shutterstock Kylie Quinn, RMIT University and Damian Purcell, The Peter Doherty Institute for Infection and Immunity SARS-CoV-2, the virus…
New international collaboration showcases drug development potential
3 April 2020 New research from Monash Institute of Pharmaceutical Sciences (MIPS), in collaboration with the Max Planck Institute, Mayo Clinic, University of Auckland, University of Essex and University of Tokyo, has uncovered new structures of protein receptors,…
CSIRO begins testing COVID-19 vaccines
2 April 2020 CSIRO, Australia’s national science agency, has commenced the first stage of testing potential vaccines for COVID-19. The testing, expected to take three months, is underway at CSIRO’s high-containment biosecurity facility, the Australian Animal Health Laboratory…
BCG vaccine trial to protect Australian healthcare workers has begun, enabled by major philanthropic backing
2 April 2020 News at a Glance The BRACE trial to test whether BCG vaccination reduces the impact of COVID-19 has begun in Melbourne 300 staff at the Melbourne Children’s Campus of the planned 4000 healthcare workers across…
Australians 65 and older become first in the world to access FLUAD® Quad
2 April 2020 Australians 65 and older have become the first in the world to access FLUAD® Quad (adjuvanted quadrivalent influenza vaccine) following addition to the National Immunisation Program in 2020(1) FLUAD® Quad is a new vaccine that…
Impact of COVID-19 on Product Development: Information and Resource from Halloran
2 April 2020 Read the full statement from Halloran here. Halloran has formed a company-wide task force to curate information on the impact to the life science industry due to the current COVID-19 environment. We are leveraging our…
Skills Australia – Essential industry survey: biopharmaceutical and medical technology manufacturing industry (lodged by Tijan Ventures & BioMelbourne Network)
Posted to web – 31 March 2020 Lodged by Tijan Ventures & BioMelbourne Network 27 March 2020 Julie Stratford Industry Engagement Manager Skills Impact By Email Dear Julie, Essential industry survey: biopharmaceutical and medical technology manufacturing industry The…
The Pratt Foundation commits $1 million to support clinical trials for COVID-19 treatments
31 March 2020 The Doherty Institute has welcomed a generous commitment of $1 million from Anthony Pratt and The Pratt Foundation, which will be directed towards the Australasian COVID-19 Trial (ASCOT). Led by the Royal Melbourne Hospital’s infectious…
Australians impacted by stomach cancer drive funding
31 March 2020 Walter and Eliza Hall Institute stomach cancer researcher Dr Lorraine O’Reilly credits a recent boost in funding from Cancer Council NSW to the support she’s received from people with stomach cancer and their carers. At a glance…
AdAlta: Business update and COVID-19 response
31 March 2020 Highlights • Preparation continues for the healthy volunteer component of AD-214 Phase I study due to start in mid-2020 • GE Healthcare (GEHC) collaboration progresses to next stage; COVID-19 mitigation actions in place • Development…
COVID-19: Guidance on clinical trials for institutions, HRECs, researchers and sponsors
31 March 2020 COVID-19: Guidance on clinical trials for institutions, HRECs, researchers and sponsors is a joint statement that reflects the shared views of all state and territory Departments of Health, the Therapeutic Goods Administration (TGA), National Health…
